The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Open accessAbstract
BACKGROUND: Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny because of reports suggesting an increased cardiovascular risk associated with their use. Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern. METHODS: We reviewed all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who were enrolled in a trial comparing two doses of celecoxib (200 mg or 400 mg twice daily) with placebo for the prevention of colorectal adenomas. All deaths were categorized as cardiovascular or noncardiovascular, and nonfatal cardiovascular events were categorized in a blinded fashion according to a prespecified scheme. RESULTS: For all patients except those who died, 2.8 to 3.1 years of follow-up data were available. A composite cardiovascular end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure was reached in 7 of 679 patients in the placebo group (1.0 percent), as compared with 16 of 685 patients receiving 200 mg of celecoxib twice daily (2.3 percent; hazard ratio, 2.3; 95 percent confidence interval, 0.9 to 5.5) and with 23 of 671 patients receiving 400 mg of celecoxib twice daily (3.4 percent; hazard ratio, 3.4; 95 percent confidence interval, 1.4 to 7.8). Similar trends were observed for other composite end points. On the basis of these observations, the data and safety monitoring board recommended early discontinuation of the study drug. CONCLUSIONS: Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure. In light of recent reports of cardiovascular harm associated with treatment with other agents in this class, these data provide further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Self-citationCardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Coxibs and Cardiovascular Disease
FitzGerald, G. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048288 · Cited by 899
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Failing the Public Health — Rofecoxib, Merck, and the FDA
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048286 · Cited by 599
Arachidonic Acid Oxygenation by COX-1 and COX-2
Marnett, L. J., Rowlinson, S. W., Goodwin, D. C., Kalgutkar, A. S., & Lanzo, C. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.22903 · Cited by 523
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Solomon, D. H., Schneeweiss, S., Glynn, R. J., Kiyota, Y., Levin, R., Mogun, H., & Avorn, J. (2004) · Circulation · doi:10.1161/01.cir.0000127578.21885.3e · Cited by 509
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Farkouh, M. E., Kirshner, H., Harrington, R. A., Ruland, S., Verheugt, F. W., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16894-3 · Cited by 490
Mamdani, M., Juurlink, D. N., Lee, D. S., Rochon, P. A., Kopp, A., Naglie, G., Austin, P. C., Laupacis, A., & Stukel, T. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16299-5 · Cited by 435
Primary Chemoprevention of Familial Adenomatous Polyposis with Sulindac
Giardiello, F. M., Yang, V. W., Hylind, L. M., Krush, A. J., Petersen, G. M., Trimbath, J. D., Piantadosi, S., Garrett, E., Geiman, D. E., Hubbard, W., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012015 · Cited by 410
Ott, E., Nussmeier, N. A., Duke, P. C., Feneck, R. O., Alston, R. P., Snabes, M. C., Hubbard, R. C., Hsu, P. H., Saidman, L. J., & Mangano, D. T. (2003) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(03)00125-9 · Cited by 403
Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease
Chenevard, R., Hürlimann, D., Béchir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R. E., Neidhart, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000051361.69808.3a · Cited by 358
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Konstam, M. A., Weir, M. R., Reicin, A., Shapiro, D., Sperling, R. S., Barr, E., & Gertz, B. J. (2001) · Circulation · doi:10.1161/hc4401.100078 · Cited by 352
Brock, T. G., McNish, R. W., & Peters-Golden, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11660 · Cited by 304
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
Crofford, L. J., Lipsky, P. E., Brooks, P., Abramson, S. B., Simon, L. S., & Van De Putte, L. B. A. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<4::aid-anr2>3.0.co;2-v · Cited by 296
Mamdani, M., Rochon, P., Juurlink, D. N., Anderson, G. M., Kopp, A., Naglie, G., Austin, P. C., & Laupacis, A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.481 · Cited by 281
Ombardier, C. L. B., Aine, L. O. L., Eicin, A. L. R., Hapiro, D. E. S., Urgos, R. U. B., Avis, B. A. D., Ay, R., Arcos, M. J., Erraz, B. O. F., Awkey, C. H. J. H., et al. (2010) · Cited by 253
Risk of cardiovascular events associated with selective COX-2 inhibitors
Mukherjee, D., Nissen, S. E., & Topol, E. J. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00545-1 · Cited by 208
Cyclooxygenase 2 inhibitors: discovery, selectivity and the future
Marnett, L. J., & Kalgutkar, A. S. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01385-1 · Cited by 205
White, W. B., Faich, G., Borer, J. S., & Makuch, R. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00659-3 · Cited by 174
Epidemiology of Non-Steroidal Anti-Inflammatory Drugs and Cancer
Baron, J. A. (2003) · Progress in Experimental Tumor Research · doi:10.1159/000071364 · Cited by 161
Lessons from the withdrawal of rofecoxib: ***
Dieppe, P. A., Ebrahim, S. B. J., Martin, R. M., & Jüni, P. (2004) · BMJ · doi:10.1136/bmj.329.7471.867 · Cited by 139
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program
Weir, M. R., SPERLING, R. S., Reicin, A. S., & Gertz, B. J. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00398-3 · Cited by 132
Parecoxib, Valdecoxib, and Cardiovascular Risk
Furberg, C. D., Psaty, B. M., & FitzGerald, G. A. (2005) · Circulation · doi:10.1161/01.cir.0000155081.76164.17 · Cited by 128
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00991-1 · Cited by 64
Mamdani, M., Juurlink, D. N., & Lee, D. S. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.07.129 · Cited by 33
Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention
Hawk, E. T., Viner, J. L., Richmond, E. S., & Umar, A. (2003) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(03)21036-x · Cited by 5
Self-citation
Cited by
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
The immune response in atherosclerosis: a double-edged sword
Hansson, G. K., & Libby, P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1882 · Cited by 2,182
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1071-1080
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158968701
- Cited by
- 2,052
- References
- 35
- FWCI
- 173.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.